Antiangiogenic activity of a bevacizumab-loaded polyurethane device in animal neovascularization models.

[1]  Min Zhao,et al.  Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats. , 2016, Investigative ophthalmology & visual science.

[2]  W. Hennink,et al.  Polyurethane-based drug delivery systems. , 2013, International journal of pharmaceutics.

[3]  F. Behar-Cohen,et al.  Montmorillonite clay based polyurethane nanocomposite as substrate for retinal pigment epithelial cell growth , 2013, Journal of Materials Science: Materials in Medicine.

[4]  R. Dana,et al.  Short-term topical bevacizumab in the treatment of stable corneal neovascularization. , 2012, American journal of ophthalmology.

[5]  F. Behar-Cohen,et al.  Biodegradable polyurethane nanocomposites containing dexamethasone for ocular route , 2011 .

[6]  H. Moreira,et al.  [Effect of subconjunctival bevacizumab on corneal neovascularization and reepithelization 25 days after chemical burn]. , 2011, Arquivos brasileiros de oftalmologia.

[7]  Osamu Sawada,et al.  Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. , 2010, Investigative ophthalmology & visual science.

[8]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[9]  Chung-Tien Lin,et al.  Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. , 2009, Investigative ophthalmology & visual science.

[10]  K. Bartz-Schmidt,et al.  Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn , 2007, Acta ophthalmologica.

[11]  R. Oréfice,et al.  Phase morphology of hydrolysable polyurethanes derived from aqueous dispersions , 2007 .

[12]  Arto Urtti,et al.  Challenges and obstacles of ocular pharmacokinetics and drug delivery. , 2006, Advanced drug delivery reviews.

[13]  Philip J Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[14]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[15]  Wei Wang,et al.  Protein aggregation and its inhibition in biopharmaceutics. , 2005, International journal of pharmaceutics.

[16]  Russell Hughes,et al.  Current methods for assaying angiogenesis in vitro and in vivo , 2004, International journal of experimental pathology.

[17]  C. Pace,et al.  Protein structure, stability and solubility in water and other solvents. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[18]  A. Vermeer,et al.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.

[19]  L. Salminen,et al.  Ocular inserts for topical delivery , 1995 .

[20]  Y. Chung,et al.  Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. , 1995, British Journal of Cancer.